New board appointment at Rib-X
This article was originally published in Scrip
Executive Summary
Rib-X Pharmaceuticals, a US development-stage company discovering and developing antibiotics for the treatment of antibiotic-resistant infections, has appointed Dr Joseph Amprey to its board of directors. He succeeds David Mott, who is continuing as an independent director of the company. Dr Amprey is senior managing director at MedImmune Ventures, a venture capital fund wholly owned by MedImmune. His appointment brings the number of Rib-X board members to 10.